# Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

## IARC TP53 Database

RRID:SCR_007731
Type: Tool

### Proper Citation

IARC TP53 Database (RRID:SCR_007731)

### Resource Information

**URL:** http://p53.iarc.fr/

**Proper Citation:** IARC TP53 Database (RRID:SCR_007731)

**Description:** The IARC TP53 Mutation Database compiles all TP53 gene variations identified in human populations and tumor samples. Data are compiled from the peer-reviewed literature and from generalist databases. The following datasets are available: # TP53 somatic mutations in sporadic cancers # TP53 germline mutation in familial cancers # Common TP53 polymorphisms identified in human populations # Functional and structural properties of P53 mutant proteins # TP53 gene status in human cell-lines # Mouse-models with engineered TP53 The database includes various annotations on the predicted or experimentally assessed functional impact of mutations, clinicopathologic characteristics of tumors and demographic and life-style information on patients. The database is meant to be a source of information on TP53 mutations for a broad range of scientists and clinicians who work in different research areas: # Basic research, to study the structural and functional aspects of the p53 protein # Molecular pathology of cancer, to understand the clinical significance of mutations identified in cancer patients # Molecular epidemiology of cancer, to analyze the links between specific exposures and mutation patterns and to make inferences about possible causes of cancer # Molecular genetics, to analyze genotype/phenotype relationships

**Abbreviations:** IARC TP53 Database

**Resource Type:** data or information resource, database

**Resource Name:** IARC TP53 Database

**Resource ID:** SCR_007731

**Alternate IDs:** nif-0000-03006

**Old URLs:** http://www-p53.iarc.fr/index.html

**Record Creation Time:** 20220129T080243+0000

**Record Last Update:** 20260905T133144+0000

## Ratings and Alerts

No rating or validation information has been found for IARC TP53 Database.

No alerts have been found for IARC TP53 Database.

## Data and Source Information

**Source:** SciCrunch Registry

## Usage and Citation Metrics

We found 160 mentions in open access literature.

**Listed below are recent publications.** The full list is available at PRECISE-TBI .


Li Y, et al. (2026) Progress in the research and development of oncolytic virus therapies. Frontiers in pharmacology, 17, 1751206.

Li S, et al. (2025) Potential application of the bulk RNA sequencing in routine MPN clinics. BMC cancer, 25(1), 746.

Perachino M, et al. (2025) Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report. Therapeutic advances in medical oncology, 17, 17588359241297565.

Fawaz S, et al. (2024) Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies. eLife, 13.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Science signaling, 17(864), eadp1375.

Qi L, et al. (2024) Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. Genes & diseases, 11(4), 101155.

Li C, et al. (2024) Unveiling correlations between aristolochic acids and liver cancer: spatiotemporal heterogeneity phenomenon. Chinese medicine, 19(1), 132.

Song R, et al. (2024) Clinical Features of Li-Fraumeni Syndrome in Korea. Cancer research and treatment, 56(1), 334.

Kibe Y, et al. (2024) Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases. Acta neuropathologica communications, 12(1), 57.

Thatikonda V, et al. (2023) Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nature cancer, 4(2), 276.

Huang Q, et al. (2023) Evaluating the prognostic significance of p53 and TP53 mutations in HPV-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study. BMC cancer, 23(1), 324.

Meirson T, et al. (2023) Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. NAR cancer, 5(1), zcac040.

Zheng E, et al. (2023) Exploration into Plasma Hsa_circ_0052184 as a New Biomarker of Colorectal Cancer Prognosis. Pharmacogenomics and personalized medicine, 16, 589.

Stružinská I, et al. (2023) A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations. Diagnostic pathology, 18(1), 72.

Sobahy TM, et al. (2022) Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows. BMC medical genomics, 15(1), 95.

Rana M, et al. (2022) A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells. Metallomics : integrated biometal science, 14(7).

d'Amati A, et al. (2022) NSD1 Mutations and Pediatric High-Grade Gliomas: A Comparative Genomic Study in Primary and Recurrent Tumors. Diagnostics (Basel, Switzerland), 13(1).

Cafforio L, et al. (2022) Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. Haematologica, 107(1), 334.

Tong X, et al. (2021) Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. The Journal of biological chemistry, 296, 100098.

Martinho MS, et al. (2021) Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers. Cellular and molecular gastroenterology and hepatology, 11(2), 449.